高消化道出血风险的非瓣膜性房颤患者口服抗凝药比较
所有NOAC较华法林降低卒中/系统性栓塞风险;阿哌沙班和达比加群降低大出血风险,利伐沙班增加大出血风险。结果提示在该高危人群中NOAC种类选择需权衡卒中预防与大出血风险。
要点
- 高消化道出血风险NVAF患者中,阿哌沙班较华法林降低卒中/系统性栓塞风险(HR 0.60,95%CI 0.52-0.68)。
- 达比加群较华法林降低卒中/系统性栓塞风险(HR 0.75,95%CI 0.64-0.88),利伐沙班亦降低(HR 0.79,95%CI 0.73-0.86)。
- 阿哌沙班(HR 0.59,95%CI 0.56-0.63)和达比加群(HR 0.78,95%CI 0.70-0.86)较华法林降低大出血风险。
- 利伐沙班较华法林增加大出血风险(HR 1.11,95%CI 1.05-1.16),在该人群中需谨慎选择。
- 该研究为回顾性队列,结果需前瞻性验证,不能直接作为床旁决策阈值。
适用人群与场景
- 非瓣膜性房颤患者,年龄≥75岁,或III-V期慢性肾脏病,或HAS-BLED评分≥3,或使用糖皮质激素/抗血小板药/NSAIDs,或存在消化道疾病。
- 数据来源为Centers for Medicare & Medicaid Services及4个商业保险数据库,2012年1月1日至2015年9月30日。
诊断标准与关键阈值
- 高消化道出血风险因素包括:年龄≥75岁;III-V期慢性肾脏病;HAS-BLED评分≥3;使用糖皮质激素、抗血小板药或NSAIDs;消化道疾病。
- HAS-BLED评分≥3定义为高出血风险(原文中74.7%患者HAS-BLED≥3)。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
- 研究暴露为新处方阿哌沙班、达比加群、利伐沙班或华法林(2013年1月1日至2015年9月30日识别期)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点卒中/系统性栓塞:阿哌沙班vs华法林HR 0.60(95%CI 0.52-0.68);达比加群vs华法林HR 0.75(95%CI 0.64-0.88);利伐沙班vs华法林HR 0.79(95%CI 0.73-0.86)。
- 大出血:阿哌沙班vs华法林HR 0.59(95%CI 0.56-0.63);达比加群vs华法林HR 0.78(95%CI 0.70-0.86);利伐沙班vs华法林HR 1.11(95%CI 1.05-1.16)。
- 采用倾向性评分匹配创建6个队列,Cox模型估计风险比。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:回顾性设计,数据来自保险数据库,可能存在混杂和未测量变量;结果需前瞻性验证。
对床旁实践的改变
- 在高消化道出血风险的非瓣膜性房颤患者中,选择NOAC时需考虑不同NOAC的大出血风险差异:阿哌沙班和达比加群较华法林降低大出血风险,利伐沙班增加大出血风险。
- 该研究结果可辅助个体化抗凝决策,但不能替代前瞻性随机试验证据。
指南或共识出处
- JAMA Netw Open
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney disease (CKD); HAS-BLED (hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age >65, drug or alcohol use) score of 3 or greater; corticosteroid, antiplatelet or nonsteroidal anti-inflammatory drug (NSAID) use; or GI conditions.
OBJECTIVE: To compare the risk of stroke and/or systemic embolism (SE) and major bleeding (MB) among patients with NVAF and high risk of GI bleeding who received non-vitamin K antagonist oral anticoagulants (NOACs) vs those who received warfarin.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with NVAF who were 75 years and older; had stage III to V CKD; had an HAS-BLED score of 3 or greater; used corticosteroids, antiplatelets, or NSAIDs; or had GI conditions. Data were collected from the Centers for Medicare & Medicaid Services and 4 commercial insurance databases between January 1, 2012, and September 30, 2015. Data analysis was conducted from January 2012 to September 2015.
EXPOSURES: New prescription for apixaban, dabigatran, rivaroxaban, or warfarin between January 1, 2013, and September 30, 2015 (identification period).
MAIN OUTCOMES AND MEASURES: Six propensity score-matched cohorts were created to compare between study drugs. For the primary objective, Cox models were used to estimate stroke and/or SE and MB hazard ratios (HRs).
RESULTS: A total of 381 054 patients (187 489 [49.2%] women) with NVAF and at least 1 high-risk GI bleeding factor were identified (HAS-BLED score ≥3: 284 527 [74.7%]; aged ≥75 years: 252 835 [66.4%]; corticosteroid, antiplatelet, or NSAID therapy: 107 675 [28.3%]; prior GI bleeding conditions: 74 818 [19.6%]; and stage III-V CKD: 56 892 [14.9%]). All NOACs were associated with a lower risk of stroke and/or SE vs warfarin (apixaban: HR, 0.60; 95% CI, 0.52-0.68; dabigatran: HR, 0.75; 95% CI, 0.64-0.88; rivaroxaban: HR, 0.79; 95% CI, 0.73-0.86). Compared with warfarin, apixaban and dabigatran were associated with a lower risk of MB (apixaban: HR, 0.59; 95% CI, 0.56-0.63; dabigatran: HR, 0.78; 95% CI, 0.70-0.86), while rivaroxaban was associated with a higher risk (HR, 1.11; 95% CI, 1.05-1.16).
CONCLUSIONS AND RELEVANCE: In this study of patients with NVAF and high risk of GI bleed, NOACs were associated with lower rates of stroke and/or SE, but NOACs had varying risks of MB compared with warfarin. These results may help inform treatment options in this patient population.
参考来源
- Lip GYH, Keshishian AV, Zhang Y, et al. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Netw Open. 2021. PMID: 34398204. doi:10.1001/jamanetworkopen.2021.20064
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。